Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract
Implementation of this OP BsAb SUD protocol is feasible with acceptable risk of CRS/ICANS and hospitalization without compromising on safety. The low incidence of CRS/ ICANS with prophylactic tocilizumab and premedication and low hospitalization rates make this appealing for selected RRMM patients.
Authors
- Nisha S. Joseph (ORCID: https://orcid.org/0000-0003-4001-9622)
- Craig C. Hofmeister (ORCID: https://orcid.org/0000-0003-4816-1607)
- Ajay K. Nooka (ORCID: https://orcid.org/0000-0003-4165-6869)
- Sagar Lonial (ORCID: https://orcid.org/0000-0002-8322-9323)
- Vikas A. Gupta (ORCID: https://orcid.org/0000-0002-8980-2338)
- Danielle Roberts (ORCID: https://orcid.org/0000-0003-1515-5702)
- Jonathan L. Kaufman (ORCID: https://orcid.org/0000-0002-5687-6429)
- Madhav V. Dhodapkar (ORCID: https://orcid.org/0000-0002-8249-5988)
- Sara A. Scott
Institutions
- Emory University (US)
Publication Details
- Journal
- Clinical Lymphoma Myeloma & Leukemia
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1016/j.clml.2025.04.002
- Citations
- 6
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 8.16